A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028

BackgroundNeoantigen-based vaccines show promising therapeutic potential in solid tumors such as melanoma, GBM, NSCLC, and CRC. However, clinical responses remain suboptimal in stage IV patients, due to ineffective T-cell function and high tumor burdens. To overcome these limitations, our study inve...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yan Zhang, Ye-Fan Hu, Lingyu Ma, Yifei Wu, Dandan Chao, Xian Chen, Zhiyuan Xu, Xiaoping Su, Wei Dai, Jiandong Huang, Pingfu Fu, Feng-Ming (Spring) Kong
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-08-01
Edice:	Frontiers in Immunology
Témata:	neoantigen vaccine radiotherapy immunotherapy T cell response low-dose radiation high-dose radiation
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1538032/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!